Added to YB: 2026-03-23
Pitch date: 2026-03-20
TVTX [bullish]
Travere Therapeutics, Inc.
Author Info
BioEquity Watch is a free, independent publication offering in-depth analysis of biotech and pharmaceutical companies, focused on market-relevant research, IPOs, and drug development pipelines. Sign up for the newsletter.
Company Info
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
Market Cap
$2.6B
Pitch Price
N/A
Price Target
42.00
Dividend
N/A
EV/EBITDA
1.1K
P/E
-49.20
EV/Sales
5.22
Sector
Biotechnology
Category
growth
DD: Travere Therapeutics ($TVTX)?
TVTX: Q4 2025 record 908 New Patient Start Forms signal nephrology community prioritizes kidney preservation over REMS burden. $42 PT (+45% upside) on dual mechanism advantage vs Novartis atrasentan. April 13 FSGS PDUFA is key catalyst: approval→$50, rejection→$24-26 floor (bounded by $491M IgAN revenue). PROTECT trial showed 1.1 mL/min/1.73m² chronic eGFR slope benefit vs irbesartan. Risk: $316M converts due 2029, hepatotoxicity stigma, quarterly monitoring vs potential REMS-free atrasentan.
Read full article (6 min)